Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients
Launched by ASTRAZENECA · May 19, 2008
Trial Information
Current as of October 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Type 2 Diabetes
- • Treatment with a stable sulphonylurea monotherapy dose that is at least half the maximal recommended dose for a minimum of 8 weeks prior to study
- • Inadequate glycaemic control, defined as A1C ≥ 7.0 % and ≤ 10%
- Exclusion Criteria:
- • Type 1 Diabetes
- • Hepatic (liver) impairment
- • Renal (kidney) failure or dysfunction
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Plzen, Czech Republic
Budapest, Hungary
Seoul, Korea, Republic Of
Manila, Philippines
Gdansk, Poland
Zabrze, Poland
Chiang Mai, Thailand
Poznan, Poland
Torun, Poland
Kiev, Ukraine
Bydgoszcz, Poland
Zalaegerszeg, Hungary
Kecskemet, Hungary
Krakow, Poland
Donetsk, Ukraine
Kharkiv, Ukraine
Sopot, Poland
Wroclaw, Poland
Plock, Poland
Chojnice, Poland
Praha 1, Czech Republic
Mosonmagyarovar, Hungary
Siofok, Hungary
Bangkok, Thailand
Eger, Hungary
Szentes, Hungary
Hodonin, Czech Republic
Miskolc, Hungary
Cebu City, Philippines
Balatonfured, Hungary
Marikina City, Philippines
Pasig City, Philippines
Semily, Czech Republic
Zielona Gora, Poland
Ruda Slaska, Poland
Chrzanow, Poland
Elblag, Poland
Zaporozhye, Ukraine
Seongnam, Korea, Republic Of
Czechowice Dziedzice, Poland
Ilawa, Poland
Incheon, Korea, Republic Of
Bekescsaba, Hungary
Wonju, Kangwon Do, Korea, Republic Of
Bucheon, Korea, Republic Of
Csongrad, Hungary
Blansko, Czech Republic
Breclav, Czech Republic
Bruntal, Czech Republic
Ostrava Belsky Les, Czech Republic
Pribram Viii, Czech Republic
Rakovnik, Czech Republic
Gyongyos, Hungary
Mako, Hungary
Tat, Hungary
Jeonju, Chonbuk, Korea, Republic Of
Suwon, Kyunggi Do, Korea, Republic Of
Uljeongbu, Korea, Republic Of
Bielsko Biala, Poland
Ciechocinek, Poland
Gniewkowo, Poland
Grudziadz, Poland
Mragowo, Poland
Zory, Poland
Dnipropetrov'sk, Ukraine
Vinnytsia, Ukraine
Patients applied
Trial Officials
Krzysztof Strojek, Prof. Dr.
Principal Investigator
Silesian Medical University3-Maja 13/15, 41-800 Zabrze; Poland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials